<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409630</url>
  </required_header>
  <id_info>
    <org_study_id>10384</org_study_id>
    <nct_id>NCT00409630</nct_id>
  </id_info>
  <brief_title>Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma</brief_title>
  <official_title>Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <brief_summary>
    <textblock>
      Subjects between the ages of 20-45 with mild to moderate asthma will be recruited. Following&#xD;
      consent, subjects will undergo an evaluation to assure no underlying metabolic bone disease.&#xD;
      Individuals will be treated with inhaled fluticasone low or high dose, daily for 3 months.&#xD;
      Serum and urine biochemical markers of bone metabolism will be collected at baseline and&#xD;
      monthly for three months. Adherence to study medication and adverse events will be collected&#xD;
      at monthly intervals. Differences between fluticasone low and high dose treated individuals&#xD;
      will be analyzed between groups and compared with baseline values.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective randomized trial. Thirty subjects with mild to moderate&#xD;
      asthma will receive inhaled fluticasone propionate. Fifteen patients will receive low dose&#xD;
      inhaled fluticasone 88 mcg twice daily. Fifteen patients will receive inhaled fluticasone 440&#xD;
      mcg twice daily. The primary outcome will be biochemical markers of bone turnover. These will&#xD;
      include 1) serum biochemical markers of bone formation [osteocalcin, bone specific alkaline&#xD;
      phosphatase (ALP) and procollagen I C-terminal propeptide (PICP)] and 2) markers of bone&#xD;
      resorption, serum collagen type 1 C-Telopeptide (CTx) urinary N-telopeptide (NTx) and&#xD;
      immunoreactive free deoxypyridinoline (iFDpd)]. Secondary endpoints will include, parathyroid&#xD;
      hormone (PTH), Urinary Calcium/creatinine, and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decided against going forward with the study.&#xD;
  </why_stopped>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone markers after 3 months of fluticasone</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin thickness measured by ultrasound biomicroscopy</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Before any study-specific procedure, the appropriate informed consent must be signed&#xD;
&#xD;
          -  Male and premenopausal female subjects&#xD;
&#xD;
          -  Age ≥ 20 years through ≤ 45 years of age&#xD;
&#xD;
          -  Documented History of Mild to moderate Asthma as defined by the NHLBI guidelines:&#xD;
&#xD;
               -  Mild Intermittent - FEV1 or PEF &gt;/= 80% predicted, PEF variability &lt;20%.&#xD;
&#xD;
               -  Mild persistent - FEV1 or PEF &gt;80% predicted, PEF variability, &gt;/= 20-30%&#xD;
&#xD;
               -  Moderate persistent - FEV1 or PEF&gt;60%-&lt;80% predicted, PEF variability &gt;30%&#xD;
&#xD;
          -  Ambulatory status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Current use of inhaled glucocorticoid therapy or use within the past 3 months. Current&#xD;
             use of leukotriene modifiers and/or inhaled bronchodilators will be allowed.&#xD;
&#xD;
          -  Use of oral glucocorticoids within the past year.&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Last menstrual period greater than 1 year ago&#xD;
&#xD;
          -  Diabetes Mellitus type 1 or 2&#xD;
&#xD;
          -  Paget's Disease, osteomalacia, hyperparathyroidism, renal osteodystrophy or other&#xD;
             metabolic bone diseases&#xD;
&#xD;
          -  History of hyperthyroidism within 1 year of randomization&#xD;
&#xD;
          -  AST or ALT &gt; 2x upper limit of normal&#xD;
&#xD;
          -  Serum creatinine greater than 2.0 mg/DL&#xD;
&#xD;
          -  History of cancer within the previous 5 years, (exceptions: excised superficial&#xD;
             lesions, such as basal or squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  The use of thiazide diuretics or anticonvulsant medications.&#xD;
&#xD;
          -  Subject is currently enrolled or has received investigational drug within 30 days&#xD;
             prior to randomization&#xD;
&#xD;
          -  Use of (within 3 months of randomization) hormones, SERMS, calcitonin, PTH (Forteo)&#xD;
&#xD;
          -  Use of (within 6 months of randomization) bisphosphonates, (Fosamax, Actonel,&#xD;
             Didronel), Vitamin D 50,000 iu&#xD;
&#xD;
          -  Use of (within 12 months of randomization) corticosteroids and/or inhaled steroids,&#xD;
             anticonvulsants. Topical and intra-articular steroids are allowed except for topical&#xD;
             steroids applied to the area where measurements of skin thickness will be made; ie.&#xD;
&#xD;
          -  Use of (within 24 months of randomization) I.V. Zometa or I.V. Aredia&#xD;
&#xD;
          -  Subject has any disorder that compromises the ability of the subject to give written&#xD;
             consent and/or to comply with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leland Graves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>December 8, 2006</study_first_submitted>
  <study_first_submitted_qc>December 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

